1. India Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Nidan Laboratories and Healthcare Limited

Nidan Laboratories and Healthcare Limited

NNSE:NIDAN
12.30
INR
-0.35
(-2.77%)
230.05MMarket Cap
Nidan Laboratories and Healthcare Limited
NSE:NIDAN
(National Stock Exchange of India)

Recent

price

12.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
INR
14.82
15.96
14.66
25.87
17.46
17.39
17.65
- -
Revenue per Share
0.16
0.51
1.66
2.32
2.55
-2.33
1.42
- -
Basic EPS, GAAP
6.44
3.32
0.81
0.66
7.41
3.44
0.96
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
7.42
7.93
9.59
47.41
49.96
47.63
49.05
49.05
Book Value per Share
7.42
7.93
9.58
47.4
49.94
47.62
49.04
49.04
Tangible Book Value per Share
14
14
14
11
14
14
14
14
Basic Weighted Avg Shares
206
222
204
297
243
242
245
- -
Sales/Revenue/Turnover
22.37
20.05
27.99
25.37
15.92
16.23
10.82
- -
Operating Margin (%)
32
32
32
26
31
29
24
- -
Depreciation Expense
2
7
23
27
35
-32
20
- -
Net Income, GAAP
- -
- -
30.28
41.09
26.44
- -
28.38
- -
Effective Tax Rate (%)
1.08
3.22
11.3
8.98
14.59
-13.37
8.06
- -
Profit Margin (%)
184
245
-33
125
113
190
10
10
Working Capital
322
344
142
94
48
43
39
39
LT Debt
103
110
133
659
694
662
682
682
Total Equity
- -
10.12
8.13
6
3.45
- -
2.58
- -
Return on Invested Capital (%)
- -
9.96
9.61
6
6.14
- -
4.38
- -
Return on Capital (%)
- -
6.7
18.9
6.72
5.23
-4.77
2.94
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Mar'23
Sep'25
Mar'25
ST Debt
62
75
72
LT Borrowings
48
43
39
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
471
458
230

Working Capital

INR

•

in mil. unless spec.
Mar'23
Sep'25
Mar'25
Total Current Assets
209
108
112
Cash, Cash Equivalents & STI
84
28
19
Accounts Receivable, Net
60
5
13
Inventories
4
3
5
Total Current Liabilities
96
111
102
Payables & Accruals
- -
- -
- -
ST Debt
62
75
72
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
83.78%
2.99%
Free Cash Flow
- -
206.69%
-72.07%
Net Income, GAAP
- -
-16.34%
-161.16%
Sales/Revenue/Turnover
- -
4.06%
1.45%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
243
2024
- -
- -
242
2025
- -
- -
245

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2.55
2024
- -
- -
-2.33
2025
- -
- -
1.42

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Mobile-health Network Solutions (NASDAQ:MNDR)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Nidan Laboratories & Healthcare Ltd (NIDAN.NS) provides diagnostic services including pathology, radiology, cardiology, and neurology across India. The company offers a comprehensive range of over 6,000 clinical laboratory tests and profiles for disease prediction, early detection, screening, confirmation, monitoring, prenatal screening, hormonal imbalance, nutritional deficiencies, and lifestyle disorders; imaging services such as computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, sonography, X-radiation, ultrasound, 2D echo, and ECG; cardiology procedures; neurology diagnostics; and health and wellness packages with value-added options like home sample collection, house calls, and report access via SMS, email, web portals, or mobile apps. It operates 35 diagnostic centers under the Nidan Diagnostics brand primarily in Greater Mumbai, targeting individual consumers, healthcare providers, and wellness-focused customers. Founded in 2000 and headquartered at Swapnshilpa, Behind Aarti Apartment, Vartak Road, Virar (West), Palghar 401303, Maharashtra, India, the company functions as the healthcare division of Nidan Group with approximately 163 employees and focuses on affordable, technology-driven diagnostics in the healthcare services sector. In recent developments, Nidan Laboratories held its 25th Annual General Meeting on September 2, 2025, where shareholders adopted the fiscal year 2025 financials, reappointed director Edwin Dabre, and approved certain related-party transactions while rejecting others; the company also issued a SEBI Regulation 74(5) certificate on October 13, 2025, confirming dematerialization compliance for the quarter ended September 30, 2025, and closed its trading window on September 24, 2025, ahead of half-year results. It reported fiscal year 2025 revenue of INR 24.53 crore, net profit of INR 1.98 crore, and a return on capital employed of 6.17%, with debtor days improving to 18.9 from prior levels amid ongoing operations in the competitive diagnostic industry.